Does low androgen signaling in postmenopausal women worsen sexual desire and GSM severity?

The decline of androgen levels during the menopausal transition plays a significant role in both sexual function and the physiological health of genitourinary tissues. In postmenopausal women, low androgen signaling is a validated contributor to decreased libido and the severity of Genitourinary Syndrome of Menopause (GSM).

Clinical and effectiveness evidence

Substantial evidence from global consensus statements confirms that androgen signaling is critical for female sexual desire and arousal.

• Sexual Function: The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy identifies Hypoactive Sexual Desire Disorder (HSDD) as the primary indication for testosterone treatment in postmenopausal women. Meta-analyses of randomized controlled trials (RCTs) show that restoring androgen levels significantly increases satisfying sexual episodes, arousal, and orgasm frequency while reducing sexual distress.
• GSM Severity: Clinical trials investigating prasterone (DHEA) and testosterone demonstrate that activating androgen pathways reduces the severity of GSM symptoms, including vaginal dryness and dyspareunia (painful intercourse). Studies show that androgen-based therapies can improve tissue health and lubrication even in women who cannot use estrogen, such as those on aromatase inhibitors for breast cancer.

Mechanistic explanations

The impact of androgens on the genitourinary system is mediated through specific receptor activity across multiple tissue layers.

• Receptor Distribution: Androgen receptors (AR) are expressed throughout the vaginal epithelium, the lamina propria (connective tissue), and the muscularis (smooth muscle) layers.
• Tissue Maintenance: Androgen signaling stimulates epithelial cell proliferation, collagen synthesis, and the maintenance of elastin fibers. It also influences the density of nerve endings and smooth muscle tone in the vaginal wall.
• Intracrinology: In postmenopausal women, the local conversion of DHEA into androgens within vaginal cells allows for "intracrine" signaling, which increases epithelial thickness and glycogen synthesis—essential for maintaining a healthy vaginal microbiome and pH.

Bottom line

Low androgen signaling is a primary driver of reduced sexual desire and contributes significantly to the physical atrophy of vulvovaginal tissues. Restoring this signaling through targeted therapy can improve libido and reduce the severity of GSM symptoms by promoting structural integrity and lubrication in the genitourinary tract.